Corebridge Financial Inc. Sells 2,389 Shares of Becton, Dickinson and Company $BDX

Key Points

• Corebridge Financial Inc. reduced its stake in Becton, Dickinson and Company by 3.6% in Q1, holding 64,041 shares valued at $14.67 million.
• Becton, Dickinson reported a quarterly EPS of $3.68, surpassing estimates, with a revenue of $5.51 billion, marking a 10.4% year-over-year increase.
• Several institutions increased their positions in Becton, Dickinson, and 86.97% of the company is owned by institutional investors and hedge funds.

Corebridge Financial Inc. lessened its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,041 shares of the medical instruments supplier's stock after selling 2,389 shares during the quarter. Corebridge Financial Inc.'s holdings in Becton, Dickinson and Company were worth $14,669,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company in the 1st quarter worth $27,000. Alpine Bank Wealth Management bought a new position in Becton, Dickinson and Company in the 1st quarter worth $29,000. REAP Financial Group LLC raised its holdings in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the period. Cornerstone Planning Group LLC raised its holdings in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA bought a new position in Becton, Dickinson and Company in the 1st quarter worth $31,000. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded up $1.59 during midday trading on Friday, reaching $192.84. 1,329,461 shares of the company traded hands, compared to its average volume of 2,590,658. The stock's 50-day simple moving average is $183.07 and its 200-day simple moving average is $194.05. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The firm has a market cap of $55.27 billion, a PE ratio of 34.68, a PEG ratio of 1.44 and a beta of 0.20. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 74.82%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price target for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Finally, Barclays reduced their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Four equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $211.44.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares in the company, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,214 shares of company stock worth $579,206 in the last three months. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.